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ABSTRACT:
Background: It is known that metabolic syndrome
characterized by diabetes, hypertension, dyslipidemia, and
central obesity is associated with the syndrome of early
vessels aging, characterized by a change in elasticity of the
vessel wall. The early manifestation of the metabolic
syndrome in younger people in the modern society, leads
to earlier manifestation of the complications of early vessels
aging, and the combination of several risk factors is crucial
and leads to acceleration of the vessels aging. Elastin is one
of the main building blocks of the of the vessel wall. Its main
characteristic is its elasticity, allowing the vessel to restore
its shape after stretching or shrinking. Loss of elasticity is
a key component in the pathogenesis of cardiovascular
complications.
Materials and methods: A study is conducted on 62
subjects with metabolic syndrome without vascular
complications and 42 controls. The main objective of the
study was to compare the imunological markers of elastin
degradation in both groups and to assess their relationship
with the risk factors characterizing the metabolic syndrome.
Results: When comparing the mean value of AEAb
IgG in the control group and subject group with metabolic
syndrome (respectively 0,45 / - 0.11 and 0.54 / - 0.29)
statistically significant higher mean value of AEAb IgG in
the group with metabolic syndrome, t = -1,85, p = 0.03 is
observed. When comparing the mean value of ATEAb IgG
in the control group and subject group with metabolic
syndrome (respectively 0,45 / - 0.13 and 0.55 / - .43)
statistically significant higher mean value of ATAb IgG in
the group with metabolic syndrome, F = 6,83, p = 0.01 is
observed. There isn’t a statistically significant difference in
AEAb IGM and ATropoEAb IgM in both groups. In the
whole sample AEAb IgG showed positive correlation with
total cholesterol with a correlation Spearman coefficient r =
0,25, and p = 0,02, with triglyceride levels with Pearson
correlation coefficient of r = 0,35, p = 0,001 and with LDL
levels with Spearman correlation coefficient r = 0,29, and p
= 0,006. In the whole sample ATropoEAb IgG showed
positive correlation with LDL levels with Spearman
correlation coefficient r = 0,29, p = 0,006 and with levels of
total cholesterol with a Pearson correlation coefficient r =
0,33, and p = 0,001. The Correlations are described by
regression analysis and the relationship is linear.
Conclusion: It is proved that the AEAb IgG and
AtropoEAb IgG are significantly elevated in the subjects
with metabolic syndrome without manifested cardiovascular
complications compared with the control group, whereas no
difference in AEAb IgM and ATropoEAb IgM has been
observed in the both groups.
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BACKGROUND:
 It is known that metabolic syndrome characterized
by diabetes, hypertension, dyslipidemia, and central obesity
is associated with the syndrome of early vessels aging,
characterized by a change in elasticity of the vessel wall.
The early manifestation of the metabolic syndrome in
younger people in the modern society, leads to earlier
manifestation of the complications of early vessels aging,
and the combination of several risk factors is crucial and
leads to acceleration of the vessels aging. Elastin is one of
the main building blocks of the of the vessel wall. Its main
characteristic is its elasticity, allowing the vessel to restore
its shape after stretching or shrinking. Loss of elasticity is
a key component in the pathogenesis of cardiovascular
complications.
Number of studies have shown that the immune
system reflects the physiological changes in the elastin
metabolism in the vascular wall. In the recent years, using
immunological methods, changes in elastin metabolism is
examined, as a sign of vascular aging in high-risk subjects
with cardiovascular complications.
There isn’t sufficient information about the nature of
the immune response against tropoelastin and elastin
metabolism in patients with metabolic syndrome without
cardiovascular complications. The data on the prognostic
value in the evaluation process of early vascular aging is
scarce. Therefore, the attempt to determine the changes in
elastin and tropoelastin metabolism in metabolic syndrome
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is one of the first steps to seek early immunological rather
than instrumental criteria to evaluate changes of the
vascular wall.
MATERIALS AND METHODS:
A study is conducted on 62 subjects with metabolic
syndrome without vascular complications and 42 controls.
The main objective of the study was to compare the
imunological markers of elastin degradation in both groups
and to assess their relationship with the risk factors
characterizing the metabolic syndrome.
RESULTS:
When comparing the average AEAb IgG in the
control group and subjects with metabolic syndrome
(respectively 0.45 + / - 0.11 and 0.54 + / - 0.29) was determined
statistically significantly higher mean values   of AEAb IgG
in the group with metabolic syndrome, t = -1,85, p = 0.03,
Figure.1.
Fig.2. Comparison between the mean AÒEAb IgG
value in healthy subjects and those with metabolic
syndrome
No significant difference was found between the
median IgM ATEAb value in healthy subjects and those
with metabolic syndrome, respectively 0.28 and 0,25, p> 0.05.
Weak correlation was determined  between the AEAb
IgG levels in the total group and total cholesterol with a
correlation coefficient of Spearman ñ = 0,25, p = 0,02.
Regression analysis best describes this dependence by a
linear model, ñ = 0,25, p = 0,02, Fig.3.
 Fig.1. Comparison between the mean AEAb IgG
value in healthy subjects and those with metabolic
syndrome
The distribution of AEAb IgM in the group of
controls and subjects with metabolic syndrome is different
from normal. When comparing the medians of the two groups
(0.34 and 0.32, respectively) no statistically significant
difference (Mann-Whitney (Wilcoxon) W test = 729.5, p =
0.06)
When comparing the average ATEAb IgG in the
group of controls and subjects with metabolic syndrome
(respectively 0.45 + / - 0.13 and 0.55 + / - 0.43) was
statistically significantly higher values   ATEAb IgG in the
group with metabolic syndrome, t = -2.638, p = 0.005, Fig. 2
Fig.3. Correlation analysis between AEAb IgG value
and total cholesterol in the total group
When evaluating the correlation between AEAb IgG
levels in the whole group and triglyceride levels,  a moderate
correlation was found with a Pearson correlation coefficient
r = 0,35, and p = 0,001. Regression analysis best describes
this relationship by a linear model, r = 0,35, p = 0,001, Fig.4./ J of IMAB. 2012, vol. 18, book 3 / 347
Fig.4. Correlation analisys between AEAb IgG levels
and triglycerides in the whole group
In addition to total cholesterol and triglycerides the
AEAb IgG levels show weak positive correlation with the
LDL levels, Spearman correlation coefficient ñ = 0,29, and p
= 0,006. Regression analysis best describes this relationship
by a linear model, ñ = 0,29, p = 0,006, fig.5
Fig.5. Correlation analysis between AEAb IgG and
the levels of LDL in the whole group
Weak but statistically significant positive correlation
was determined between the levels of a ATEAb IgG in the
whole group with total cholesterol levels with Pearson’s r =
0,25, and p = 0,02. Regression analysis best describes this
relationship which is linear, r = 0,25, p = 0,02, fig.6.
Statistically significant, moderate, positive correlation
was determined when assessing the correlation between
ATEAb IgG and total cholesterol levels in the general group
with Pearson correlation coefficient r = 0,33, and p = 0,001.
Regression analysis best describes this relationship which
is linear, r = 0,33, p = 0,001, fig.7
 Fig.6. Correlation analysis between ATEAb IgG and
total cholesterol levels in the whole group
Fig.7. Correlation analysis between IgG ATEAb and
triglyceride levels in the total group
CONCLUSION:
The changes in the immunological markers against
elastin and tropoelastin, showed that antibodies from class
IgG, characterising the secondary immune response, are
elevated in the long-term chronic inflammation
characterising the metabolic syndrome and atherosclerosis,
respectively, the vascular aging process. Therefore, the
constellation of elevated AEAb IgG, ATEAb IgG, can be
used as an early marker of vascular aging.
The following conclusion can be made: dyslipidemia
and its inherent hypertriglyceridemia is one of the laboratory
criteria for metabolic syndrome, Characterising the increased
insulin resistancy. Increased insulin resistancy affects the
turnover of elastin and tropoelastin. The correlation between
elevated levels of AEAb IgG, ATEAb IgG, and triglycerides
adequately reflects the process of vascular aging,
apparently orchestrated by insulin resistance and therefore
can be discussed as a constellation, which is a sure sign of
early vascular aging.348 / J of IMAB. 2012, vol. 18, book 3 /
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